Professional
Added to YB: 2025-08-14
Pitch date: 2025-08-07
CRSP [bullish]
CRISPR Therapeutics AG
-2.83%
current return
Author Info
No bio for this author
Company Info
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
Market Cap
$5.1B
Pitch Price
$56.23
Price Target
N/A
Dividend
N/A
EV/EBITDA
-6.57
P/E
-8.27
EV/Sales
959.56
Sector
Biotechnology
Category
growth
RGA Investment Advisors New Position: CRISPR Therapeutics AG
CRSP (new position): Leading CRISPR gene therapy firm with approved product Casgevy. Shares fell from $90 to $30 in April crash despite trade war having minimal impact. Enterprise value <$800M with $1.8B net cash. Strong balance sheet allows pipeline advancement while competitors retrench. Asymmetric setup: buying Casgevy at discount, getting pipeline & cash free.
Read full article (1 min)